Chloroquine and Hydroxychloroquine in Treatment of Coronavirus Disease-19
Keywords:COVID-19, pandemic, treatment, chloroquine, hydroxychloroquine
At present, we are facing coronavirus disease (COVID)-19 pandemic caused by the severe acute respiratory syndrome coronavirus-2 with several treatment choices and reports of different treatment outcomes. Chloroquine and hydroxychloroquine use for the management of severely ill patients started as a quite enthusiastic treatment option, following several small clinical trials, case series reports, public authorities, and media affirmation. However, the evidence we have so far is conflicting and some national societies and professional institutions implicate that we should wait for definite treatment recommendations until there are solid data for or against the use of these drugs. Until we have more powerful evidence in our hands, we should be aware of safety issues of the old drugs for the new application in the emergency state we are facing today with the COVID-19 pandemic. We performed a concise review of strengths, limitations, and awareness for chloroquine and hydroxychloroquine use for COVID-19 infection treatment based on the evidence the science has today.
Plum Analytics Artifact Widget Block
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71. https://doi.org/10.1038/s41422-020-0282-0 PMid:32020029
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-3. https://doi.org/10.5582/bst.2020.01047 PMid:32074550
Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;9:ciaa237. https://doi. org/10.1093/cid/ciaa237 PMid:32150618
Food and Drug Administration. Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of Hydroxychloroquine Sulfate Supplied from the Strategic National Stockpile for Treatment of COVID-19 in Certain Hospitalized Patients; 2020. Available from: https://www.fda. gov/media/136537/download. [Last accessed on 2020 May 01].
Al-Bari AA. Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases. Pharm Res Per. 2017;5(1):e00293. https://doi. org/10.1002/prp2.293 PMid:28596841
Al-Bari MA. Chloroquine analogues in drug discovery: New directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70(6):1608-21. https://doi. org/10.1093/jac/dkv018 PMid:25693996
Savarino A, Boelaert JR, Cassone A. Effects of chloroquine on viral infections: An old drug against today’s diseases? Lancet Infect Dis. 2003;3(11):722-7. https://doi.org/10.1016/ s1473-3099(03)00806-5 PMid:14592603
Gautret P, Lagier JC, Parola P, Hoang V, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;20:105949. https://doi. org/10.1101/2020.03.22.20040949 PMid:32205204
Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020;49(2):215-9. PMid:32391667
Borba MG, Val FF, Sampaio VS, Alexandre MA, Melo GC, Brito M, et al. Cloro covid-19 team. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857. https://doi. org/10.1001/jamanetworkopen.2020.8857 PMid:32339248
Barbosa J, Kaitis D, Freedman R. Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID- 19: A quasi-randomized comparative study. N Engl J Med 2020;1:8882.
Chen Z, Hu J, Zhang Z. Efficacy of Hydroxychloroquine in Patients with COVID-19: Results of a Randomized Clinical Trial. ChiCTR2000029559; 2020.
Lagier JC, Fenollar F, Lepidi H, Lepidi H, Giorgi R, Million M, et al. Treatment of classic Whipple’s disease: From in vitro results to clinical outcome. J Antimicrob Chemother 2014;69(1):219-27. PMid:23946319
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID- 19. Int J Antimicrob Agents 2020;55(4):105932. https://doi. org/10.1016/j.ijantimicag.2020.105932 PMid:32145363
Capel RA, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, et al. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential. Heart Rhythm. 2015;12(10):2186-94. https://doi.org/10.1016/j. hrthm.2015.05.027 PMid:26025323
Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic COVID-19-and-Cardiology/ESC-COVID-19-Guidance; 2020. https://doi.org/10.1002/bjs.11646
Roden DM, Harrington RA, Poppas A, Russo AM. Drug interactions on QTc in exploratory COVID-19 treatment. Circulation 2020;2020:1161. https://doi.org/10.1161/ circulationaha.120.047521 PMid:32267732
Tisdale JE, Jayes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes. 2013;6(4):479-87. https://doi. org/10.1161/circoutcomes.113.000152 PMid:23716032
Simpson TF, Kovacs RJ, Stecker EC. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-azithromycin Treatment for COVID-19. Cardiology Magazine; 2020.
How to Cite
Copyright (c) 2020 Lidija Poposka, Irena Mitevska (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.